Quarterly Shareholder Report and Appendix 4C

• Positive top-line Phase 2a data for amsulostat (SNT-5505) in myelofibrosis
• FDA feedback provides clinical development pathway for amsulostat
• Initiated AZALOX Phase 1b/2 trial for myelodysplastic neoplasms

Syntara Ltd, a clinical-stage drug development company, has reported a summary of its activities for the quarter ended 30 September 2025. The company reported positive top-line Phase 2a data for amsulostat (SNT-5505) in myelofibrosis (MF), with 73% of patients achieving ≥ 50% symptom improvement and 44% achieving ≥ 25% spleen volume reduction, with durable benefits and no treatment-related serious adverse events up to 12 months. The FDA has provided feedback on the clinical development pathway for the advancement of amsulostat in MF, and Syntara has appointed a group of internationally recognised haematology and biopharmaceutical experts to provide clinical and strategic guidance. The company has also initiated the AZALOX Phase 1b/2 trial in Germany for myelodysplastic neoplasms, and dosed the first participants in the SNT-9465 (hypertrophic scars) and SNT-6302 (keloid scars) Phase 1 studies. Syntara maintains a strong cash position of $14.4 million.

Syntara reported a closing cash balance of $14.4 million at the end of the September quarter, compared to $15.1 million at 30 June 2025. The net cash outflow of $0.7 million was driven by operating cashflows, predominantly offset by the receipt of $5.6 million of proceeds from the R&D tax incentive.